Pulmonary Hypertension News and Research RSS Feed - Pulmonary Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Elevated endothelial progenitor cells may characterise PAH patients

Elevated endothelial progenitor cells may characterise PAH patients

Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers. [More]
Pulmonary hypertension impacts walking ability in SSc patients

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis. [More]

More evidence for combination therapy benefits in PAH

Another meta-analysis adds to evidence of increased benefits for patients with pulmonary arterial hypertension who are given combination therapy. [More]
Detailed digital models of human organs could bring substantial benefits to clinical trials

Detailed digital models of human organs could bring substantial benefits to clinical trials

Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today. [More]
Novel gene therapy can treat pulmonary hypertension linked with heart failure

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai. [More]
Hydrocortisone drug can also prevent lung damage in premature babies

Hydrocortisone drug can also prevent lung damage in premature babies

Research from Ann & Robert H. Lurie Children's Hospital of Chicago conducted in mice shows the drug hydrocortisone -- a steroid commonly used to treat a variety of inflammatory and allergic conditions -- can also prevent lung damage that often develops in premature babies treated with oxygen. [More]
Meta-analysis supports combination therapy for PAH patients

Meta-analysis supports combination therapy for PAH patients

A meta-analysis shows that clinical worsening is significantly less likely in patients with pulmonary arterial hypertension if they are given combination treatment, rather than monotherapy. [More]
Minimally important dyspnoea, fatigue changes in PAH patients defined

Minimally important dyspnoea, fatigue changes in PAH patients defined

Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension. [More]
Increased BMP7 levels predict PAH mortality

Increased BMP7 levels predict PAH mortality

Elevated levels of circulating bone morphogenetic protein 7 are associated with an increased mortality risk in patients with pulmonary arterial hypertension, find Chinese researchers. [More]
BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data. [More]
Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Scleroderma is an autoimmune disease that affects one out of every 10,000 people in Europe and North America, mostly middle-aged women, and causes death in a high percentage of cases. [More]
Inhalable form of Ambrisentan drug could offer faster-acting treatment option for pulmonary edema

Inhalable form of Ambrisentan drug could offer faster-acting treatment option for pulmonary edema

In a new study, researchers show an aerosolized, inhalable form of the drug Ambrisentan could offer a faster-acting treatment option for pulmonary edema, a life-threatening condition in which fluid accumulates in the lungs. Pulmonary edema is a significant risk for anyone spending time at high altitudes, and also affects people with chronic conditions including congestive heart failure and sickle cell anemia. [More]
Study could lead to potential new therapeutic target with fewer side effects for hypertension

Study could lead to potential new therapeutic target with fewer side effects for hypertension

A team of Vermont investigators has been issued a patent for their discovery of a molecule that rescues damaged blood vessels, yet preserves healthy vessels and could serve as a springboard for a new pharmaceutical therapy with fewer side effects for hypertension - a major risk factor for cardiovascular and kidney disease that effects roughly one in three people in the U.S. [More]
Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation progresses in line with right ventricular remodelling and increasing pulmonary artery systolic pressure in patients with pulmonary arterial hypertension, research shows. [More]
Regulatory immune cells compromised in PAH

Regulatory immune cells compromised in PAH

Research suggests that regulatory T cells may play a part in all subtypes of pulmonary arterial hypertension. [More]
PAH role proposed for left heart failure biomarker

PAH role proposed for left heart failure biomarker

Levels of galectin-3 are elevated in patients with pulmonary arterial hypertension and correlate with disease severity, research shows. [More]
Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body [More]
UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

Heidi M. Mansour, PhD, assistant professor in the University of Arizona College of Pharmacy, is working to develop advanced dry powder inhalers to treat and prevent pulmonary diseases. [More]
Pulmonary neuroendocrine cells act like sensor to orchestrate immune response

Pulmonary neuroendocrine cells act like sensor to orchestrate immune response

An uncommon and little-studied type of cell in the lungs has been found to act like a sensor, linking the pulmonary and central nervous systems to regulate immune response in reaction to environmental cues. [More]
Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Laboratorios SALVAT, S.A. and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited, jointly announced today the signing of an exclusive License and Supply Agreement for the marketing and distribution of Duoxal ear drops (patented combination solution of Ciprofloxacin and Fluocinolone Acetonide) in the People's Republic of China, Hong Kong S.A.R., Macau S.A.R., and Taiwan and an option to add Thailand to the contractual territory. [More]
Advertisement
Advertisement